LIWANLI Innovation Co., Ltd. (TPE:3054)
Taiwan · Delayed Price · Currency is TWD 65.00
+0.40 (0.62%)
Mar 26, 2026, 1:30 PM CST
LIWANLI Innovation Revenue
In the year 2025, LIWANLI Innovation had annual revenue of 125.54M TWD with 26.61% growth. LIWANLI Innovation had revenue of 23.90M in the quarter ending December 31, 2025, with 38.23% growth.
Revenue
125.54M
Revenue Growth
+26.61%
P/S Ratio
41.76
Revenue / Employee
n/a
Employees
n/a
Market Cap
5.24B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 125.54M | 26.38M | 26.61% |
| Dec 31, 2024 | 99.16M | 60.27M | 154.98% |
| Dec 31, 2023 | 38.89M | 4.90M | 14.41% |
| Dec 31, 2022 | 33.99M | -13.83M | -28.91% |
| Dec 31, 2021 | 47.81M | -229.07M | -82.73% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Formosa Laboratories | 4.85B |
| Orient EuroPharma | 4.60B |
| Handa Pharmaceuticals | 1.62B |
| Maywufa Company | 1.58B |
| Orient Pharma | 1.40B |
| SCI Pharmtech | 1.34B |
| Allied Biotech | 849.51M |
| Easywell Biomedicals | 597.41M |